GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
were further supported in part by funding from the Eric and Wendy Schmidt Center at the Broad Institute of MIT and Harvard
The structure reveals a closed conformation in which the peptide-binding region of the ECD interacts with the extracellular regions of the TMD
TRIUMPH-4 Phase III: 28.7% weight loss at 68 weeks highest ever recorded.Retatrutide vs Semaglutide vs TirzepatideRetatrutide: 28.7% weight loss (68 wk) Triple agonist (GLP-1+GIP+GCGR)Tirzepatide (Mounjaro/Zepbound): 22.5% (72 wk) Dual agonist (GLP-1+GIP)Semaglutide (Wegovy/Ozempic): 15-17% (68 wk) GLP-1 onlyKey Clinical Results (April 2026)TRIUMPH-4 Phase III (Dec 2025): 28.7% body weight reduction, 71.2 lbs lost at 12mg doseTRANSCEND-T2D-1 (Mar 2026): 2.0% HbA1c reduction, 16.8% weight loss in type 2 diabetesPhase II (NEJM 2023): 24.2% weight loss at 48 weeks, no plateau observedFDA NDA submission: Q4 2026-Q1 2027Research-Grade RetatrutideBioInfinity Lab GLP3-R: 99%+ purity, third-party COA verified, GMP compliant
Marking the fourth and fifth positive readouts for the drug, TRIUMPH-2 (NCT05929079) and TRIUMPH-3 (NCT05882045) evaluated the first-in-class glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon triple hormone receptor agonist
